Abvc Biopharma (ABVC) Change in Receivables (2012 - 2023)
Abvc Biopharma's (ABVC) quarterly Change in Receivables came in at -$37292.0 in Q4 2023, down 106.4% on a YoY basis from $582257.0 in Q4 2022, and down 284.45% quarter-over-quarter from -$9700.0 in Q3 2023.
Powered by 
Analysis
Abvc Biopharma (ABVC) Change in Receivables (2012 - 2023) Analysis & Trends
Abvc Biopharma (ABVC) has reported Change in Receivables for 8 consecutive years, with -$37292.0 the latest figure, recorded in Q4 2023.
- For the quarter ending Q4 2023, Change in Receivables fell 106.4% year-over-year to -$37292.0; the trailing twelve-month figure through Dec 2023 stood at -$228557.0 (down 137.21% YoY), and the FY2023 full-year result was -$228557.0, down 137.21% from the prior year.
- Change in Receivables fell to -$37292.0 in Q4 2023 per ABVC's latest filing, from -$9700.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $582257.0 in Q4 2022 and bottomed at -$156436.0 in Q3 2019.
- Historically, Change in Receivables has averaged $32155.3 across 5 years, with a median of -$4597.5 in 2022.
- The sharpest annual moves came in 2019 and 2023: Change in Receivables jumped 1961.93% in 2019, then slumped 22543.37% in 2023.
- Over 5 years, Change in Receivables stood at $18212.0 in 2019, then jumped by 246.41% to $63088.0 in 2020, then slumped by 180.32% to -$50675.0 in 2021, then jumped by 1249.0% to $582257.0 in 2022, then sank by 106.4% to -$37292.0 in 2023.
- According to Business Quant data, Change in Receivables over the past three periods registered -$37292.0, -$9700.0, and -$68226.0 for Q4 2023, Q3 2023, and Q2 2023 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 1.09 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 333.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 140.20 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 838.50 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -53.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 31.60 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 269.40 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Abvc Biopharma | 25.56 Mn | 25.56 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | -37,292.00 |
| Sep 30, 2023 | -9,700.00 |
| Jun 30, 2023 | -68,226.00 |
| Mar 31, 2023 | -113,339.00 |
| Dec 31, 2022 | 582,257.00 |
| Sep 30, 2022 | 23,127.00 |
| Jun 30, 2022 | 8,277.00 |
| Mar 31, 2022 | 505.00 |
| Dec 31, 2021 | -50,675.00 |
| Sep 30, 2021 | -47,365.00 |
| Jun 30, 2021 | -19,464.00 |
| Mar 31, 2021 | 238,484.00 |
| Dec 31, 2020 | 63,088.00 |
| Sep 30, 2020 | -87,155.00 |
| Jun 30, 2020 | 92,795.00 |
| Mar 31, 2020 | -52,950.00 |
| Dec 31, 2019 | 18,212.00 |
| Sep 30, 2019 | -156,436.00 |
| Jun 30, 2019 | 142,629.00 |
| Mar 31, 2019 | 116,334.00 |